Exploiting DNA mismatch repair deficiency as a therapeutic strategy

Experimental Cell Research

Volumn 329, Issue 1, 2014, Pages 110-115

  Guillotin, Delphine ^a   Martin, Sarah A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Drug resistance; Mismatch repair; Synthetic lethality; Therapeutics

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; ATM PROTEIN; ATR PROTEIN; CARBOPLATIN; CHECKPOINT KINASE RAD3; CISPLATIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; METHOTREXATE; MICRORNA 155; MISMATCH REPAIR PROTEIN; PROTEIN MLH1; PROTEIN MSH2; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DNA;

DNA REPLICATION; DOUBLE STRANDED DNA BREAK; ENDOMETRIUM CANCER; EXCISION REPAIR; GERMLINE MUTATION; GLIOBLASTOMA; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR PROTEIN DEFICIENCY; NEOPLASM; OVARY CANCER; PROTEIN DEFICIENCY; RECTUM CANCER; REVIEW; ANIMAL; DRUG EFFECTS; GENETICS; MISMATCH REPAIR; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA MISMATCH REPAIR; DNA, NEOPLASM; HUMANS; NEOPLASMS;

EID: 84919423844     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.07.004     Document Type: Review

References (39)

1. Hsieh P., Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech. Ageing Dev. 2008, 129(7-8):391-407.
2. Li G.M. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008, 18(1):85-98.
3. Liu A., Yoshioka K., Salerno V., Hsieh P. The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine. J. Cell. Biochem. 2008, 105(1):245-254.
4. Brierley D.J., Martin S.A. Oxidative stress and the DNA mismatch repair pathway. Antioxid. Redox Signal. 2013, 18(18):2420-2428.
5. Stojic L., Brun R., Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair 2004, 3(8-9):1091-1101.
6. Wada-Hiraike O., Yano T., Nei T., Matsumoto Y., Nagasaka K., Takizawa S., Oishi H., Arimoto T., Nakagawa S., Yasugi T., et al. The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor alpha. Br J. Cancer 2005, 92(12):2286-2291.
7. Smith J.A., Bannister L.A., Bhattacharjee V., Wang Y., Waldman B.C., Waldman A.S. Accurate homologous recombination is a prominent double-strand break repair pathway in mammalian chromosomes and is modulated by mismatch repair protein Msh2. Mol. Cell Biol. 2007, 27(22):7816-7827.
8. Aarnio M., Mecklin J.P., Aaltonen L.A., Nystrom-Lahti M., Jarvinen H.J. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int. J. Cancer J. Int. du Cancer 1995, 64(6):430-433.
9. Xiao X., Melton D.W., Gourley C.: Mismatch repair deficiency in ovarian cancer - molecular characteristics and clinical implications. Gynecol. Oncol. 2013.
10. Wang Q., Lasset C., Desseigne F., Frappaz D., Bergeron C., Navarro C., Ruano E., Puisieux A. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res. 1999, 59(2):294-297.
11. Imai K., Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 2008, 29(4):673-680.
12. Resnick K.E., Frankel W.L., Morrison C.D., Fowler J.M., Copeland L.J., Stephens J., Kim K.H., Cohn D.E. Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. Gynecol. Oncol. 2010, 117(2):234-238.
13. Beggs A.D., Domingo E., Abulafi M., Hodgson S.V., Tomlinson I.P.: A study of genomic instability in early preneoplastic colonic lesions. Oncogene 2012.
14. Souza R.F., Appel R., Yin J., Wang S., Smolinski K.N., Abraham J.M., Zou T.T., Shi Y.Q., Lei J., Cottrell J., et al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat. Genet. 1996, 14(3):255-257.
15. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275(5302):967-969.
16. Duval A., Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res. 2002, 62(9):2447-2454.
17. Hewish M., Lord C.J., Martin S.A., Cunningham D., Ashworth A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat. Rev. Clin. Oncol. 2010, 7(4):197-208.
18. Fink D., Aebi S., Howell S.B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. an Off. J. Am. Assoc. Cancer Res. 1998, 4(1):1-6.
19. Yip S., Miao J., Cahill D.P., Iafrate A.J., Aldape K., Nutt C.L., Louis D.N. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res. an Off. J. Am. Assoc. Cancer Res. 2009, 15(14):4622-4629.
20. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3(5):330-338.
21. Hemminki A., Mecklin J.P., Jarvinen H., Aaltonen L.A., Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000, 119(4):921-928.
22. Popat S., Hubner R., Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 2005, 23(3):609-618.
23. Jover R., Zapater P., Castells A., Llor X., Andreu M., Cubiella J., Balaguer F., Sempere L., Xicola R.M., Bujanda L., et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur. J. Cancer 2009, 45(3):365-373.
24. Martin L.M., Marples B., Coffey M., Lawler M., Lynch T.H. Hollywood D, Marignol L: DNA mismatch repair and the DNA damage response to ionizing radiation: making sense of apparently conflicting data. Cancer Treat. Rev. 2010, 36(7):518-527.
25. Meyers M., Hwang A., Wagner M.W., Bruening A.J., Veigl M.L., Sedwick W.D., Boothman D.A. A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 2003, 22(47):7376-7388.
26. Roos W.P., Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013, 332(2):237-248.
27. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5(9):689-698.
28. Martin S.A., McCabe N., Mullarkey M., Cummins R., Burgess D.J., Nakabeppu Y., Oka S., Kay E., Lord C.J., Ashworth A. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer cell 2010, 17(3):235-248.
29. Martin S.A., McCarthy A., Barber L.J., Burgess D.J., Parry S., Lord C.J., Ashworth A. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med. 2009, 1(6-7):323-337.
30. Martin S.A., Hewish M., Sims D., Lord C.J., Ashworth A. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res. 2011, 71(5):1836-1848.
31. Hewish M., Martin S.A., Elliott R., Cunningham D., Lord C.J., Ashworth A. Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress. Br J. Cancer 2013, 108(4):983-992.
32. Vilar E., Scaltriti M., Balmana J., Saura C., Guzman M., Arribas J., Baselga J., Tabernero J. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J. Cancer 2008, 99(10):1607-1612.
33. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921.
34. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):913-917.
35. Vilar E., Bartnik C.M., Stenzel S.L., Raskin L., Ahn J., Moreno V., Mukherjee B., Iniesta M.D., Morgan M.A., Rennert G., et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011, 71(7):2632-2642.
36. Zhang J., Stevens M.F., Laughton C.A., Madhusudan S., Bradshaw T.D. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 2010, 78(2):103-114.
37. Valeri N., Gasparini P., Fabbri M., Braconi C., Veronese A., Lovat F., Adair B., Vannini I., Fanini F., Bottoni A., et al. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(15):6982-6987.
38. Li F., Mao G., Tong D., Huang J., Gu L., Yang W., Li G.M. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSalpha. Cell 2013, 153(3):590-600.
39. Goeliner E.M., Grimme B., Brown A.R., Lin Y.C., Wang X.H, Sugrue K.F., Mitchell L., Trivedi R.N., Tang J.B., Sobol R.W. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res 2011, 71:2308-2317.